Upstream Bio presented positive Phase 2 trial results for verekitug, a new antibody treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). About 80% of patients showed meaningful improvement in nasal polyp scores after treatment every three months, with significant benefits in nasal congestion and symptom relief. Verekitug targets the TSLP receptor, a key driver of inflammation, and is the only drug in development with this mechanism. The company plans to start Phase 3 trials for CRSwNP and severe asthma in early 2027, aiming to offer a convenient and effective new biologic therapy.
On World Blood Donor Day, June 14, 2026, more than 100 organizations in the US united to thank the 8 million annual blood donors and encourage more eligible people to donate. Blood donations are critical as a transfusion is needed every two seconds i...
The Phase 3 SENTRY trial showed that combining selinexor (NEXPOVIO®) with ruxolitinib significantly improved spleen volume reduction by 49.8% at week 24 compared to 28% with ruxolitinib alone in myelofibrosis patients. This combination also showed a ...
The daily transaction fees on the XRP Ledger have dropped below $400, signaling a decrease in network activity. This decline raises concerns about the current usage and demand for the XRP network. Investors and users are watching closely to see if th...
XRP has stabilized above the key $1 support level after a sharp drop from $1.30, with selling pressure fading between $1.05 and $1.10. This suggests sellers are losing conviction, but it is not yet a bullish reversal. For a clear uptrend, XRP needs t...
The Fidelity Enhanced International ETF (FENI) has grown to $8.1 billion in assets, paying variable quarterly dividends from over 350 international companies. Its income is backed by stable dividends from well-capitalized firms like Novartis, HSBC, a...
